This bill shifts the regulation of laboratory developed tests (LDTs) entirely to CLIA standards, establishes new validity requirements, mandates a centralized database, and updates CLIA regulations to reflect modern laboratory science.
Neal Dunn
Representative
FL-2
The Enhancing CLIA Act of 2026 fundamentally shifts the regulation of Laboratory Developed Tests (LDTs) from the FDA's medical device framework entirely under the CLIA framework administered by HHS. This legislation establishes new standards for analytical and clinical validity for LDTs and mandates the creation of a centralized database for transparency. Furthermore, the Act requires updates to CLIA specialties to reflect modern laboratory science and mandates greater public input on regulatory guidance.
Enhancing CLIA Act of 2026 Moves Lab Test Oversight to HHS: New Standards for Validity Kick Off in Two Years.
If you’ve ever had a specialized blood test or a high-tech genetic screen that wasn't a standard 'off-the-shelf' kit, you’ve likely used a Laboratory Developed Test (LDT). Currently, the FDA treats these like medical devices, but the Enhancing CLIA Act of 2026 is about to flip the script. Starting two years after this bill passes, oversight of these tests moves entirely away from the FDA’s device framework and into the hands of the Department of Health and Human Services (HHS) under the Clinical Laboratory Improvement Amendments (CLIA). The goal is to treat a lab test like a service provided by a doctor’s office rather than a piece of hardware, defining exactly what 'validity' means for the results you get back from the lab.
The New Rules of Validation
Under this bill, labs can only run these tests for clinical use if they can prove 'analytical validity' (the test accurately measures what it says it does) and 'clinical validity' (the result actually matters for your health). For you, this means a lab-developed cancer screen or a prenatal test has to meet a specific legal standard of reliability before it hits your doctor’s desk. To keep everyone honest, HHS will build a massive, searchable web database within two years. Labs will have to upload their test names, what they’re testing for, and a summary of the evidence proving the test actually works. If you’re curious whether that expensive new diagnostic your specialist recommended is legit, you’ll theoretically be able to look it up yourself.
Reporting Mistakes and Moving Fast
One of the biggest shifts is how the government handles it when things go wrong. If a test gives a wrong result that leads to a serious injury or death, labs are on a strict clock: they must report the error to HHS within five days. For less critical but still serious errors, they’ll report quarterly. This is a big deal for patient safety, as it creates a paper trail for tests that aren't performing well in the real world. If HHS finds a test is consistently failing the 'validity' test, they can force the lab to stop running it within 45 days. It’s a 'trust but verify' system that gives labs more freedom to innovate quickly but holds a hammer over them if they put out junk science.
Cutting the FDA Red Tape
For the tech-savvy or those in the medical field, the most interesting part is the 'Optional Third-Party Supplemental Affirmation.' Basically, labs can choose to have a third party—including the FDA—vouch for their test to get a gold star of approval. While this is optional, having that affirmation makes it much easier for insurance like Medicare to cover the cost. The bill also forces the government to update its lab categories to include 21st-century tech like digital pathology and next-generation sequencing. While this could lead to faster breakthroughs and more personalized medicine, the shift away from the FDA’s strict 'medical device' rules means we’re relying heavily on HHS to be a tough watchdog. If they aren't, the burden of spotting a faulty test might fall more on patients and their doctors than it does today.